## **REMARKS**

In this Preliminary Amendment, Applicant has amended Claims 1, 5-11, 13, 14, 27, 31, 32, and 34, and cancelled Claims 2 and 36-44. Claims 1 and 3-35 are currently pending in this Application. The amendments introduce no new matter. Support for the amendments can be found in the Specification and claims as filed, and especially in pages 32-44 of the Specification wherein definitions for several of the terms used in the claims are provided. The Applicant respectfully requests allowance of all pending claims.

Respectfully submitted,

Michael Schmelzer, Reg. No. 43,093

Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800

Telephone: 908-231-4797 Telefax: 908-231-2626

Docket No. USA3960 US CNT